Great Lakes Retirement Inc. Purchases 943 Shares of Zoetis Inc. $ZTS

Great Lakes Retirement Inc. increased its position in Zoetis Inc. (NYSE:ZTS) by 8.0% in the 2nd quarter, Holdings Channel reports. The firm owned 12,719 shares of the company’s stock after buying an additional 943 shares during the quarter. Great Lakes Retirement Inc.’s holdings in Zoetis were worth $1,984,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Nuveen LLC acquired a new stake in shares of Zoetis in the first quarter valued at $616,375,000. Mackenzie Financial Corp increased its stake in shares of Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after buying an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC increased its stake in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Amundi increased its stake in shares of Zoetis by 30.8% in the first quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after buying an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its stake in shares of Zoetis by 475.9% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after buying an additional 743,926 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of ZTS stock opened at $144.25 on Friday. The stock has a 50-day moving average price of $147.15 and a 200 day moving average price of $153.36. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm has a market cap of $63.93 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $183.11.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s revenue was up 4.2% on a year-over-year basis. During the same period last year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. UBS Group lowered their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research note on Monday, October 20th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Argus reiterated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and an average target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.